Sight Sciences
- Company typePublic
- Founded2006
- HeadquartersMenlo Park, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Sight Sciences firmographics
Firmographics- Name
- Sight Sciences
- Legal name
- Sight Sciences, Inc.
- Website
- https://sightsciences.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Sight Sciences industry classification
Industry- Product category
- Interventional Ophthalmic Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
- akta.pro primary industry
- Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)
- akta.pro secondary industry
- Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)
Keywords
Where Sight Sciences is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Sight Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Revenue model
- Surgical Glaucoma Devices: Sale of OMNI Surgical System, OMNI Edge Surgical System, and SION Surgical Instrument to eyecare providers for use in glaucoma surgery procedures. Revenue is generated from device sales to ophthalmic surgeons and practices.
- Interventional Dry Eye: Sale of TearCare System components including SmartLids (single-use consumables) and SmartHub hardware to eyecare providers for dry eye treatment procedures.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Medical device products sold to healthcare providers through commercial and Medicare channels |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Sight Sciences product offering
Product offeringCore offering
Sight Sciences develops, manufactures, and commercializes interventional ophthalmic medical devices for the treatment of glaucoma and dry eye disease. Its product portfolio includes the OMNI Surgical System and OMNI Edge (implant-free, single-use MIGS devices that perform canaloplasty and trabeculotomy to reduce intraocular pressure), the SION Surgical Instrument (a bladeless single-use goniotomy device), and the TearCare System (a 510(k)-cleared localized heat therapy system with SmartLids and SmartHub components for treating meibomian gland dysfunction). Products are sold directly to eyecare providers including ophthalmologists and optometrists through a dedicated field sales organization, with Medicare reimbursement coverage and clinical training support.
Product overview
Sight Sciences is an eyecare technology company that develops and commercializes interventional technologies for treating glaucoma and dry eye disease. The company's product portfolio consists of three core surgical devices: the OMNI Surgical System and its newer variant OMNI Edge Surgical System (both implant-free MIGS devices for reducing intraocular pressure in glaucoma patients), the SION Surgical Instrument (a bladeless goniotomy device), and the TearCare System (a localized heat therapy device for treating dry eye disease caused by meibomian gland dysfunction). The products are designed for minimally invasive procedures targeting the underlying causes of prevalent eye diseases, enabling eyecare providers to intervene earlier in disease progression.
Differentiator
Problem solved
Functional benefit
Brands
- OMNI Surgical System: Implant-free, minimally invasive glaucoma surgery (MIGS) technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
- OMNI Edge Surgical System
- SION Surgical Instrument
- TearCare System
- Sight Access
Products and services
- OMNI Surgical System
Quantifiable outcome
- SAHARA RCT demonstrated TearCare superiority over Restasis in TBUT and meibomian gland secretion scores at 6 months, with durability through 24 months with two treatments in first 5 months.
- +4 more outcomes
Companies that use Sight Sciences
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles2 records
Sight Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Sight Sciences partnerships and signals
Strategic signalScale indicators9 records
Recent moves6 records
Expansion highlights5 records
Sight Sciences competitors and assessment
Company assessmentDirect peers
- Glaukos Corporation: Direct MIGS competitor with the iStent and iStent Infinite platforms, plus an interventional dry eye program. Competes head-to-head with Sight Sciences' OMNI for MIGS procedural share in glaucoma surgeon accounts.
- Lumenis: Develops and sells the OptiLight IPL system for meibomian gland dysfunction / dry eye disease, directly competing with Sight Sciences' TearCare in optometry and ophthalmology offices.
Broad incumbents
- Alcon: Global ophthalmic incumbent and the rival whose Hydrus Microstent competes with OMNI; subject of Sight Sciences' patent infringement suit. Broad portfolio across cataract, glaucoma, vitreoretinal and dry eye (iTear, Systane).
- Johnson & Johnson Vision: Diversified eye care leader with cataract surgery, contact lens and dry eye portfolios (TearScience LipiFlow historically); competes for the same surgeon and optometrist customers as Sight Sciences.
- Carl Zeiss Meditec: Sells ophthalmic surgical microscopes, IOLs and diagnostics to the same ophthalmic surgery centers where OMNI, SION and TearCare are sold, making it a meaningful adjacent competitor and partner candidate.
Emerging players
- New World Medical: Recent FDA-cleared novel MIGS devices give ophthalmologists additional canal-based alternatives to OMNI, intensifying competition in the standalone MIGS segment.
- BVI Medical: Acquired multiple MIGS-related assets and launched new canal-based devices in 2024-2025, positioning BVI as a fast-follower competing for MIGS case share.
- Ocular Therapeutix: Sustained drug-delivery ophthalmic products (e.g., DEXTENZA) that overlap with Sight Sciences' interventional glaucoma positioning and compete in the same ASC and clinic accounts.
Regional players
- RxSight: Commercial-stage ophthalmic device company selling the Light Adjustable Lens and related postoperative adjustment system; targets the same cataract surgeon channel where OMNI is combined with cataract surgery.
- NovaBay Pharmaceuticals: Markets Aganocide ophthalmic solutions (e.g., i-Click and prescription Avenova) targeting ocular surface and dry eye; smaller but adjacent to TearCare in optometry channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Sight Sciences social profiles
Digital presenceSight Sciences compliance and trust
Trust signalCompliance2 records
Sight Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sight Sciences leadership team
Management profileNumber of profiles
Profiles13 records
Sight Sciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
Sight Sciences funding detail
Funding detailFunding overview
Funding rounds8 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sight Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sight Sciences
What does Sight Sciences do?
Sight Sciences develops, manufactures, and commercializes interventional ophthalmic medical devices for the treatment of glaucoma and dry eye disease. Its product portfolio includes the OMNI Surgical System and OMNI Edge (implant-free, single-use MIGS devices that perform canaloplasty and trabeculotomy to reduce intraocular pressure), the SION Surgical Instrument (a bladeless single-use goniotomy device), and the TearCare System (a 510(k)-cleared localized heat therapy system with SmartLids and SmartHub components for treating meibomian gland dysfunction). Products are sold directly to eyecare providers including ophthalmologists and optometrists through a dedicated field sales organization, with Medicare reimbursement coverage and clinical training support.
Is Sight Sciences a public or private company?
Sight Sciences is a public company. It is classified as public and is currently operating.
When was Sight Sciences founded?
Sight Sciences was founded in 2006. It employs 101 to 250 people.
Where is Sight Sciences based?
Sight Sciences is headquartered in Menlo Park, United States, in the North America region.
How does Sight Sciences make money?
Two revenue lines are on record. Surgical Glaucoma Devices are the primary driver. The others are interventional Dry Eye.
Who are Sight Sciences's main competitors?
Direct peers on record are Glaukos Corporation and Lumenis. Broad incumbents are Alcon, Johnson & Johnson Vision and Carl Zeiss Meditec. Emerging players are New World Medical, BVI Medical and Ocular Therapeutix. Regional players are RxSight and NovaBay Pharmaceuticals.
Does Sight Sciences have an API?
No public API is recorded for Sight Sciences.
What industry is Sight Sciences in?
Sight Sciences's product category is Interventional Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty), with a secondary code of HLAHAJAF, Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation). Its NAICS code is 339115 and its SIC code is 3841.